SCHEDULE 13G/A
SCHEDULE 13G/ASchedule 13G ownership disclosure
ADVERUM BIOTECHNOLOGIES INC
Common Stock, $0.0001 par value per share · CUSIP: 00773U207
Event date: 2025-11-25
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Frazier Life Sciences Public Fund, L.P.
Shares: 4,288,949.00 · Class: 19.4%
- FHMLSP, L.P.
Shares: 4,288,949.00 · Class: 19.4%
- FHMLSP, L.L.C.
Shares: 4,288,949.00 · Class: 19.4%
- Frazier Life Sciences X, L.P.
Shares: 216,964.00 · Class: 1.0%
- FHMLS X, L.P.
Shares: 216,964.00 · Class: 1.0%
- FHMLS X, L.L.C.
Shares: 216,964.00 · Class: 1.0%
- Frazier Life Sciences XI, L.P.
Shares: 504,849.00 · Class: 2.3%
- FHMLS XI, L.P.
Shares: 504,849.00 · Class: 2.3%
- FHMLS XI, L.L.C.
Shares: 504,849.00 · Class: 2.3%
- Frazier Life Sciences XII, L.P.
Shares: 522,768.00 · Class: 2.4%
- FHMLS XII, L.P.
Shares: 522,768.00 · Class: 2.4%
- FHMLS XII, L.L.C.
Shares: 522,768.00 · Class: 2.4%
- James N. Topper
Shares: 216,964.00 · Class: 1.0%
- Patrick J. Heron
Shares: 216,964.00 · Class: 1.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001231919-25-000559
- Form type
- SCHEDULE 13G/A
- Filer
- Adverum Biotechnologies, Inc.
- CIK
- CIK 1501756
- Filed
- Nov 28, 2025
- Reporting period
- Nov 25, 2025
- Description
- Schedule 13G beneficial ownership